Shoulo thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study  by Roth, Arie et al.
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1 and enh~~eme~t of survival (f,g). Any delay 
h~rn~~yt~~ ~~y has a critaeal impact on the 
~~~~~~ation Therefore, the prehos- 
the: mqjsr front i4 the battle for revascu- 
~~~~~dy et al. (9) to state that ‘“the 
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istration of r~~ornb~~ant t~~~~~~~~y~~ ~lasmiu~gem activator 
@t-PA) in the mobile intensive care unit, which in Israel is 
staRed by a physician or intern as well as by paramedics. 
These were 1) age 473 years, 2) severe 
my~cardial ischemic hest pain for 330 
than 4 h, and 3) ST segment elevation of 
0.1 mV or more in at least two contiguous ele~t~oc~d~o- 
graphic (KG) leads. 
Exclusion criteria. Ttiese were 1) diastoiic blood pressure 
>I20 mm Hg, 2) left bundle brunch block on the qualifying 
entry KG, 3) history of congestive heart failure or cardiac 
(for instarxe, oral a~tic~~a~~~~a~t therapy, recent trauma, past 
bl~edi~~~ history, or ce~ebr~vascu~ar acc~de~~l wiulin the iast 
6 months). 
after signing an informed consent a~reemenl were allocated 
on an alternating monthly rotation basis to receive prehos- 
pital thrombolytic treatment by the mobile intensive care 
unit team or thrombolytic therapy in the coronary care unit 
(87 patients). An additional successive 29 patients who 
enrolled th er received prehospital 
apy via the le intensive care unit. T 
maintained telemetric commumicat~o~ with the medical cent- 
ter. All patients were continuous 
mias and vital signs were obtain 
tra tat il arrival (Fig. 1). ’ 
re A total dose of 120 mg of rccomb~~~ant 
tissue-type plasminogen activator (rt-PA) (Grl1035, supplied 
by Boehrittger Ingelheim, West Germany) was administered 
over a 6 h period, consisting of a 10 mg bolus followed by 
pe~ormed in the anterior and 45” left anterior oblique 
projections. Left ventricular ejection fictions were detcr- 
mined and all radionuclide exarn~~at~~~s were assessed by 
ilalized in the corona 
ood samples were also 
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plasminogen activity, fibrinogen level and partial thrombo- 
plastin time at baseline. 
S&II Y&a ata are expressed as mean values f 
1 standard deviation unless otherwise tated. Student’s I test 
was used to compare groups with approximately normal 
distribution, while nonparametric g oup comparisons were 
evaluated using the Mann-Whitney IJ test. The chi square 
test or Wilcoxon test was used for unpaired samples. 
r to receive treatment 
spital coronary caIy3 unit 
care unit. Two patients in group A were excluded from 
c6 Of asymptomatic accelerated id- 
s were observed in two patients in group 
B. Three patients in group Aand wo in 
degrees of bradyarrhythmias w thout 
compromise that required intervention. 
Table 1. Baseline Characteristics n Patients Assigne 
Recombinant Tissue-Type Plasminogen Activator @t-PA) in the 
Mobile Intensive Care Unit (MICU) (group A) and in the 
Coronary Care Unit (CCtJ) (group B) 
Age iyrb 
Gender (% men) 
Body mass index (kg/m21 
Hypertension (%I 
Smekon (%,) 
Diabetes mellitus (%I 
Angina pectoris (!JQ 
Previous infarct (%h) 
Systolic blood pressure (mm Ngl 
Heart rate (~e;~ts/fl~~~) 
Killip scale (%I 
I UP 2 
30r4 
Location of infarct (%I 
Anterior 
Inferior 
Fibrinol)cn (rn~~~ ml) 
Plasminogea activity (954 
No. of diseased vessels (%I* 
I 
2 or more 
~nfar~t~relate~ coronary artery (95) 
Left anterior descending 
Left cirsumfkzx 
58 2 9 
82 
26 & 3 
20 
50 
I4 
NS 
NS 
NS 
N 
0.05 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
MS 
MS 
NS 
NS 
NS 
NS 
NS 
*Sixty-five patients in group A and 43 Patients in group 
~t~~~tone~ in two patients. 
only three patients requiring bl 
Tabk 2. Time to Thrombolytic Therapy, Enzyme Release, Left 
~ent~c~~ar Ejection Fraction on Admission and Patency of the 
tnf~~~t-~~~at~d Artery inthe Two Patient Groups 
Group A Group B P 
(MICU, n = 72) (CCU. n = 44) Value 
Time to therapy (min) 94 ” 35 137 r: 45 
CK peak (ICI) 1346 + 1541 It 939 
CK AUC (IIJ) 7109 + 6882 + 4856 NS 
LVEF (%) 47 5 M (43*) 48 + 15 (41*) NS 
IRA patent (o/n! 82 (65%) 77 143*1 NS 
*No. of patients examined. AUC = area under the curve; CK = cmatine 
kinase; IRA = infarct-related coronary artery; LVEF = left ventricular 
ejection fraction. Other abbrevia:ions as in Table 1. 
The rec~g~itiQn of the i~~o~tanc~ of early a~~licaFi~~ of 
thrombolytic therapy in myocardial ~~fa~~tio~ led 
to the investigation oT i~ist~Fi0~ of Iytic 
mber of ~e~Q~ed ~atic~ts 
Table 4. In-Hospital Clinical Course in the Two Patient Groups 
Group A Group 13 P 
ChJkOlrmfZ (NICU. n = 72) KCU,n = 44) Value 
Bleeding (%) 14 9 NS 
PTCA (%I 42 (65”) 56 (43? NS 
CABG (%) 7 s NS 
Reinfafction (%) 13.9 13.6 NS 
Mortality (%‘c) 5.5 6.R NS 
LtnEih of stav Idw;s) 11 I4 NS 
*No. of patients catheterized. CABG = coronary artery bypass graft; 
RCA = percutaneous transluminal coronary angioplasty. Other abbrevia- 
tions as in Table I. 
intravenous reco 
slotted ~~r~~a~y artery. 
hospital patients can be tr 
(82% versus 77%), there was an increased left v~~t~i~~~~r 
ejection fraction (49 -‘- 17% vbrsus 45 &t 1995) a 
trends in favor of 
Fhrombolytic trial ( I&) 
ventricdar function, patients wko had an anterior infarction 
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benefited from early thrombolytic treatment more than those 
who had an inferior infarction. We compared the global left 
ventricular ejection fraction of patients with anterior infarc- 
tion treated in the mobile unit (n = 33) with that of patients 
treated in the coronary care unit (n = 19) but did not observe 
any difference, Hoiiever, the small number of patients pre- 
cludes any conclusions being drawn, the same being true for 
the corresponding patients with inferior infarction Gable 5). 
The GISSl study (5) demonstrated that in-hospital mor- 
t&y was reduced when thcr.zpy was given within 3 h of 
more so when treatment wits initiated 
tion. The ISAM trial (19) also indicated 
point for improved survival, but other 
t that the therapeutic “window” may 
My if thrambolysis is combined with 
angioplasty. Studies compar 
and performed in Jerusalem, 
myocardial salvage, few incorrect diagnoses and a 
ncc of repcrfusion arrhythmias, hemorrhage .;r 
other complications (I 1.21.22). 
?%a rerlson3 we were uronhle to demon.stmte ~i~n~~~~~lt 
br?nefit of earlier treatment mcry he one or both of the 
following: I) the 44 min delay may have keen too short to 
display significant difference: 2) although streptokinasc may 
lose its effectiveness with time, recombinnnt tissue-type 
plasminogen activator retains a h h cfkacy even with u 
longer delay (10,231. for early t~r~~r~bolysis 
thus remains very st 
nstntes that myocar- 
nosed and that early 
administration of recombinant tiss pc pl~srnin~~~e~ acti- 
vator by a mobile intensive cBre unit team is feasible and 
We were unable to demonstrate a signifi- 
le outcome in the prehospital early treatment 
we believe that the evidence 
be time element in 
the 
thrombol the 
n the latt ventricular ejection fraction and 
tive heart failure in the prehospital grwp ~uppm the 
pt’ehospital thrombolysis in the routine management 
nts with acute myocardial infarction, 
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